Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open prospective randomized study of zoledronic acid to prevent bone loss in newly diagnosed HIV patients starting antiretroviral therapy
MOH_2024-11-17_013738Phase 4Recruiting
- Sponsor
- ד"ר הילה אלינב
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in human immunodeficiency virus infection (HIV) (4 arms), sponsored by ד"ר הילה אלינב. Started Oct 2024; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on MOH_2024-11-17_013738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-17_013738.